Accepted Manuscript

Title: A subtype-specific Neuropeptide FF receptor antagonist attenuates morphine and nicotine withdrawal syndrome in the rat

Authors: David H. Malin, Mallori M. Henceroth, Joanne Elayoubi, Joseph R. Campbell, Andrea Anderson, Pilar Goyarzu, Jonathon Izygon, Caitlin A. Madison, Christopher P. Ward, Ethan S. Burstein

PII: S0304-3940(18)30456-7

DOI: https://doi.org/10.1016/j.neulet.2018.06.053


Reference: NSL 33684

To appear in: Neuroscience Letters

Received date: 15-12-2017 Revised date: 21-6-2018 Accepted date: 28-6-2018

Please cite this article as: Malin DH, Henceroth MM, Elayoubi J, Campbell JR, Anderson A, Goyarzu P, Izygon J, Madison CA, Ward CP, Burstein ES, A subtype-specific Neuropeptide FF receptor antagonist attenuates morphine and nicotine withdrawal syndrome in the rat, *Neuroscience Letters* (2018), https://doi.org/10.1016/j.neulet.2018.06.053

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



A subtype-specific Neuropeptide FF receptor antagonist attenuates morphine and nicotine withdrawal syndrome in the rat

David H. Malin^{1*}, Mallori M. Henceroth¹, Joanne Elayoubi¹, Joseph R. Campbell¹, Andrea Anderson¹, Pilar Goyarzu¹, Jonathon Izygon¹, Caitlin A. Madison¹, Christopher P. Ward¹, Ethan S. Burstein².

¹University of Houston-Clear Lake, 2700 Bay Area Blvd. Houston, TX 77058, U.S.A.

²ACADIA Pharmaceuticals Inc., 3611 Valley Centre Dr. Suite 300, San Diego, CA 92130, U.S.A.

*Corresponding author: David H. Malin, Ph.D. University of Houston-Clear Lake (Mail code 265) 2700 Bay Area Blvd., Houston, TX 77058 U.S.A.

malin@uhcl.edu

Highlights

- AC-262620 is a small-molecule, systemically active, selective antagonist of the FF1 receptor.
- Ten mg/kg i.p. AC-262620 significantly reduced naloxone-precipitated somatically expressed withdrawal signs in rats infused s.c. for seven days with 0.3 mg/kg/hr morphine sulfate.
- The same dose of AC-262620 significantly reduced subsequent spontaneous withdrawal signs 23.75 hours after termination of seven days s.c. infusion of 0.6 mg/kg/hr morphine sulfate.
- Nicotine triggers the release of endogenous opioid peptides. Additional evidence suggests that endogenous opiate mechanisms may contribute to nicotine withdrawal syndrome in the rat.
- AC-262620 significantly reduced somatically expressed withdrawal signs precipitated by 1 mg/kg s.c. of the nicotinic antagonist mecamylamine in rats infused for seven days with 9 mg/kg/day nicotine bitartrate.

Download English Version:

https://daneshyari.com/en/article/8841336

Download Persian Version:

https://daneshyari.com/article/8841336

<u>Daneshyari.com</u>